| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 49 | 2018 | 254 | 6.620 |
Why?
|
| Schizophrenic Psychology | 35 | 2016 | 88 | 3.050 |
Why?
|
| Antipsychotic Agents | 19 | 2017 | 300 | 2.430 |
Why?
|
| Psychotic Disorders | 11 | 2018 | 138 | 1.690 |
Why?
|
| Psychomotor Disorders | 4 | 2015 | 12 | 1.170 |
Why?
|
| Schizotypal Personality Disorder | 3 | 2010 | 5 | 1.100 |
Why?
|
| Family Health | 2 | 2015 | 75 | 1.060 |
Why?
|
| Association | 4 | 2012 | 4 | 0.890 |
Why?
|
| Marijuana Abuse | 2 | 2018 | 16 | 0.860 |
Why?
|
| Cognition Disorders | 12 | 2016 | 203 | 0.810 |
Why?
|
| Neuropsychological Tests | 20 | 2016 | 290 | 0.780 |
Why?
|
| Marijuana Use | 1 | 2018 | 10 | 0.740 |
Why?
|
| Psychiatric Status Rating Scales | 22 | 2017 | 401 | 0.690 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 200 | 0.640 |
Why?
|
| Adult | 67 | 2018 | 13301 | 0.630 |
Why?
|
| Motivation | 1 | 2018 | 252 | 0.620 |
Why?
|
| Male | 67 | 2018 | 23420 | 0.560 |
Why?
|
| Functional Laterality | 6 | 2015 | 122 | 0.530 |
Why?
|
| Schizophrenic Language | 11 | 1991 | 13 | 0.520 |
Why?
|
| Electroconvulsive Therapy | 1 | 2013 | 14 | 0.510 |
Why?
|
| Humans | 92 | 2018 | 48363 | 0.510 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2013 | 27 | 0.500 |
Why?
|
| Speech Disorders | 1 | 2012 | 17 | 0.490 |
Why?
|
| Female | 60 | 2018 | 26304 | 0.490 |
Why?
|
| Psychomotor Performance | 5 | 2010 | 137 | 0.470 |
Why?
|
| Motor Activity | 4 | 2016 | 325 | 0.450 |
Why?
|
| Clozapine | 5 | 2007 | 35 | 0.450 |
Why?
|
| Endophenotypes | 1 | 2010 | 6 | 0.440 |
Why?
|
| Executive Function | 2 | 2013 | 49 | 0.430 |
Why?
|
| Mental Recall | 7 | 2013 | 117 | 0.420 |
Why?
|
| Cocaine | 4 | 1993 | 74 | 0.400 |
Why?
|
| Child Development | 1 | 2010 | 74 | 0.390 |
Why?
|
| Adolescent | 14 | 2018 | 5503 | 0.390 |
Why?
|
| Verbal Behavior | 2 | 2007 | 34 | 0.380 |
Why?
|
| Schizophrenia, Paranoid | 4 | 2006 | 6 | 0.360 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 171 | 0.360 |
Why?
|
| Cognition | 5 | 2007 | 343 | 0.350 |
Why?
|
| Individuality | 1 | 2007 | 20 | 0.350 |
Why?
|
| Risperidone | 4 | 2016 | 29 | 0.350 |
Why?
|
| Thinking | 11 | 2005 | 39 | 0.340 |
Why?
|
| Young Adult | 7 | 2018 | 3673 | 0.340 |
Why?
|
| Movement Disorders | 5 | 1997 | 24 | 0.320 |
Why?
|
| Neurologic Examination | 4 | 2010 | 45 | 0.320 |
Why?
|
| Psychopathology | 1 | 2005 | 15 | 0.310 |
Why?
|
| Psychology, Clinical | 1 | 2005 | 8 | 0.310 |
Why?
|
| Electroencephalography | 4 | 2016 | 103 | 0.310 |
Why?
|
| Neurology | 1 | 2005 | 22 | 0.310 |
Why?
|
| Memory Disorders | 2 | 2013 | 39 | 0.300 |
Why?
|
| Speech | 6 | 1991 | 48 | 0.280 |
Why?
|
| Brain | 5 | 2016 | 1135 | 0.270 |
Why?
|
| Risk | 3 | 2015 | 388 | 0.270 |
Why?
|
| Research | 1 | 2005 | 187 | 0.270 |
Why?
|
| Models, Psychological | 2 | 2018 | 97 | 0.260 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 380 | 0.260 |
Why?
|
| Substance-Related Disorders | 4 | 1993 | 567 | 0.260 |
Why?
|
| Paranoid Disorders | 3 | 1996 | 5 | 0.260 |
Why?
|
| Thiazoles | 2 | 2013 | 44 | 0.260 |
Why?
|
| Research Design | 3 | 2007 | 528 | 0.250 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 246 | 0.250 |
Why?
|
| Verbal Learning | 2 | 2000 | 21 | 0.250 |
Why?
|
| Piperazines | 2 | 2013 | 95 | 0.240 |
Why?
|
| Analysis of Variance | 3 | 2013 | 556 | 0.240 |
Why?
|
| Reaction Time | 4 | 2016 | 104 | 0.230 |
Why?
|
| Placebos | 2 | 2001 | 75 | 0.230 |
Why?
|
| Memory | 3 | 2006 | 95 | 0.220 |
Why?
|
| Middle Aged | 35 | 2017 | 13617 | 0.220 |
Why?
|
| Attention | 6 | 2013 | 153 | 0.220 |
Why?
|
| Mentally Ill Persons | 1 | 2001 | 50 | 0.220 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 2310 | 0.210 |
Why?
|
| Delusions | 3 | 1996 | 15 | 0.210 |
Why?
|
| Social Alienation | 1 | 2000 | 1 | 0.210 |
Why?
|
| Psychometrics | 3 | 2010 | 345 | 0.200 |
Why?
|
| Brain Mapping | 4 | 2013 | 189 | 0.200 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 1186 | 0.200 |
Why?
|
| Language | 2 | 2013 | 113 | 0.200 |
Why?
|
| Depressive Disorder | 7 | 2006 | 280 | 0.180 |
Why?
|
| Evoked Potentials | 2 | 2016 | 27 | 0.180 |
Why?
|
| Psychoses, Substance-Induced | 2 | 1988 | 8 | 0.180 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 309 | 0.180 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 27 | 0.170 |
Why?
|
| Mental Disorders | 5 | 1989 | 659 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2016 | 1333 | 0.170 |
Why?
|
| Affective Disorders, Psychotic | 3 | 2013 | 20 | 0.160 |
Why?
|
| Receptors, Dopamine | 1 | 2016 | 10 | 0.160 |
Why?
|
| Phenotype | 2 | 2012 | 997 | 0.160 |
Why?
|
| Dopamine Antagonists | 1 | 2016 | 14 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2007 | 748 | 0.160 |
Why?
|
| Informed Consent | 2 | 2011 | 120 | 0.160 |
Why?
|
| Semantics | 4 | 2013 | 56 | 0.160 |
Why?
|
| Mood Disorders | 3 | 1992 | 55 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 53 | 0.150 |
Why?
|
| Dopamine | 1 | 2016 | 76 | 0.150 |
Why?
|
| Neurocognitive Disorders | 3 | 1988 | 8 | 0.150 |
Why?
|
| Patient Readmission | 2 | 2016 | 348 | 0.150 |
Why?
|
| Word Association Tests | 2 | 2012 | 3 | 0.150 |
Why?
|
| Benzodiazepines | 2 | 2013 | 80 | 0.140 |
Why?
|
| Event-Related Potentials, P300 | 1 | 2013 | 4 | 0.140 |
Why?
|
| Frontal Lobe | 3 | 2000 | 59 | 0.130 |
Why?
|
| Writing | 2 | 1987 | 43 | 0.130 |
Why?
|
| Time Factors | 7 | 2016 | 3232 | 0.130 |
Why?
|
| Mental Competency | 2 | 2011 | 61 | 0.130 |
Why?
|
| Bipolar Disorder | 4 | 2013 | 219 | 0.130 |
Why?
|
| Sulpiride | 1 | 2013 | 1 | 0.130 |
Why?
|
| Aripiprazole | 1 | 2013 | 9 | 0.130 |
Why?
|
| Hospitalization | 3 | 2012 | 1058 | 0.130 |
Why?
|
| Disease Progression | 1 | 2016 | 691 | 0.130 |
Why?
|
| Reality Testing | 2 | 2007 | 2 | 0.130 |
Why?
|
| Patient Admission | 1 | 1994 | 162 | 0.130 |
Why?
|
| Quinolones | 1 | 2013 | 26 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2016 | 298 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 375 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2013 | 126 | 0.120 |
Why?
|
| Reference Values | 1 | 2012 | 329 | 0.120 |
Why?
|
| Hospitals, Psychiatric | 2 | 1999 | 57 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2010 | 884 | 0.110 |
Why?
|
| Object Attachment | 1 | 1991 | 24 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2012 | 249 | 0.110 |
Why?
|
| Decision Making | 3 | 2013 | 322 | 0.110 |
Why?
|
| Personality Inventory | 1 | 2010 | 61 | 0.110 |
Why?
|
| Prevalence | 2 | 2010 | 1127 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 1992 | 191 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1988 | 126 | 0.110 |
Why?
|
| Recurrence | 3 | 2017 | 510 | 0.110 |
Why?
|
| China | 1 | 2010 | 106 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2007 | 481 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2009 | 72 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 590 | 0.100 |
Why?
|
| Age Factors | 3 | 2004 | 1447 | 0.100 |
Why?
|
| Psychiatry | 2 | 2001 | 103 | 0.090 |
Why?
|
| Chronic Disease | 4 | 1999 | 690 | 0.090 |
Why?
|
| United States | 5 | 2017 | 6149 | 0.090 |
Why?
|
| Dioxoles | 1 | 2007 | 3 | 0.090 |
Why?
|
| Brain Diseases | 1 | 1988 | 40 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 1988 | 84 | 0.090 |
Why?
|
| Algorithms | 1 | 2013 | 886 | 0.090 |
Why?
|
| Mental Status Schedule | 2 | 1990 | 19 | 0.090 |
Why?
|
| Piperidines | 1 | 2007 | 35 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 43 | 0.080 |
Why?
|
| Schizophrenia, Disorganized | 1 | 1986 | 1 | 0.080 |
Why?
|
| Albinism | 1 | 1986 | 2 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2016 | 3823 | 0.080 |
Why?
|
| Age of Onset | 3 | 2012 | 166 | 0.080 |
Why?
|
| Brain Injuries | 1 | 1988 | 121 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 1211 | 0.080 |
Why?
|
| Minnesota | 1 | 2005 | 19 | 0.080 |
Why?
|
| Language Disorders | 1 | 2005 | 18 | 0.080 |
Why?
|
| Periodicity | 1 | 2005 | 54 | 0.080 |
Why?
|
| Demography | 1 | 2006 | 179 | 0.080 |
Why?
|
| Injections | 2 | 2016 | 75 | 0.070 |
Why?
|
| Motor Skills | 2 | 1984 | 55 | 0.070 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 95 | 0.070 |
Why?
|
| Risk Factors | 3 | 2012 | 4225 | 0.070 |
Why?
|
| Hospitals, Public | 1 | 1984 | 6 | 0.070 |
Why?
|
| Aged | 9 | 2006 | 10909 | 0.070 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1984 | 9 | 0.070 |
Why?
|
| Community Mental Health Centers | 1 | 1984 | 22 | 0.070 |
Why?
|
| Hospitals, State | 1 | 1984 | 16 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2010 | 1779 | 0.070 |
Why?
|
| Software | 1 | 2007 | 325 | 0.070 |
Why?
|
| Biofeedback, Psychology | 3 | 1980 | 6 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2005 | 224 | 0.070 |
Why?
|
| Stuttering | 2 | 1980 | 5 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 1996 | 763 | 0.070 |
Why?
|
| Memory, Short-Term | 2 | 2013 | 48 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 114 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2006 | 348 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 1993 | 96 | 0.060 |
Why?
|
| Hypertension | 1 | 2007 | 528 | 0.060 |
Why?
|
| Agranulocytosis | 1 | 2001 | 7 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2002 | 36 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 855 | 0.060 |
Why?
|
| Raynaud Disease | 2 | 1979 | 5 | 0.060 |
Why?
|
| Control Groups | 1 | 2001 | 10 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 1994 | 286 | 0.060 |
Why?
|
| Psychoanalytic Theory | 2 | 1995 | 2 | 0.050 |
Why?
|
| Child | 1 | 2010 | 3807 | 0.050 |
Why?
|
| Comorbidity | 2 | 1996 | 996 | 0.050 |
Why?
|
| Dyskinesia, Drug-Induced | 2 | 1994 | 11 | 0.050 |
Why?
|
| Paired-Associate Learning | 2 | 1996 | 3 | 0.050 |
Why?
|
| Behavior Therapy | 2 | 1979 | 159 | 0.050 |
Why?
|
| Lithium | 3 | 2001 | 16 | 0.050 |
Why?
|
| Visual Perception | 2 | 2016 | 41 | 0.050 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 1999 | 12 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2013 | 727 | 0.050 |
Why?
|
| Antidepressive Agents | 2 | 1996 | 207 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2000 | 206 | 0.050 |
Why?
|
| Perceptual Disorders | 1 | 1998 | 6 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 1998 | 31 | 0.050 |
Why?
|
| Obesity | 1 | 2007 | 1171 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 1996 | 1962 | 0.050 |
Why?
|
| Face | 1 | 1998 | 26 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 1978 | 44 | 0.050 |
Why?
|
| Length of Stay | 2 | 1996 | 617 | 0.050 |
Why?
|
| Bahamas | 2 | 1988 | 18 | 0.050 |
Why?
|
| Family | 2 | 1996 | 199 | 0.040 |
Why?
|
| Handwriting | 1 | 1997 | 1 | 0.040 |
Why?
|
| Fingers | 2 | 2016 | 40 | 0.040 |
Why?
|
| Dementia | 3 | 1988 | 170 | 0.040 |
Why?
|
| Interview, Psychological | 2 | 2012 | 78 | 0.040 |
Why?
|
| Electromyography | 3 | 1983 | 74 | 0.040 |
Why?
|
| ROC Curve | 1 | 2017 | 235 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2016 | 19 | 0.040 |
Why?
|
| Hallucinations | 1 | 1996 | 16 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 2046 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 408 | 0.040 |
Why?
|
| Personality Assessment | 1 | 1995 | 28 | 0.040 |
Why?
|
| Internal-External Control | 1 | 1995 | 38 | 0.040 |
Why?
|
| Psychotherapy | 1 | 1996 | 83 | 0.040 |
Why?
|
| Haloperidol | 1 | 1974 | 21 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2013 | 538 | 0.040 |
Why?
|
| Social Behavior | 1 | 1994 | 80 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 262 | 0.030 |
Why?
|
| Language Tests | 1 | 2013 | 31 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2013 | 82 | 0.030 |
Why?
|
| Long QT Syndrome | 1 | 2013 | 24 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1994 | 168 | 0.030 |
Why?
|
| Seizures | 1 | 1994 | 70 | 0.030 |
Why?
|
| Wechsler Scales | 1 | 2013 | 12 | 0.030 |
Why?
|
| Arousal | 1 | 1993 | 46 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 2012 | 7 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 414 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 101 | 0.030 |
Why?
|
| Deinstitutionalization | 1 | 1992 | 9 | 0.030 |
Why?
|
| Oxygen | 1 | 2013 | 236 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 54 | 0.030 |
Why?
|
| Haplotypes | 1 | 2012 | 116 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2012 | 90 | 0.030 |
Why?
|
| Tape Recording | 1 | 1991 | 10 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 181 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2007 | 561 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 116 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 1994 | 373 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2002 | 2722 | 0.030 |
Why?
|
| Eye Movements | 2 | 1983 | 80 | 0.030 |
Why?
|
| Psychological Theory | 2 | 1983 | 27 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2013 | 479 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2011 | 150 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 2492 | 0.030 |
Why?
|
| Alleles | 1 | 2012 | 403 | 0.030 |
Why?
|
| Lymphocytosis | 1 | 1990 | 6 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 417 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1989 | 68 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1990 | 115 | 0.020 |
Why?
|
| Alcoholism | 1 | 2012 | 261 | 0.020 |
Why?
|
| Basal Ganglia Diseases | 2 | 1982 | 7 | 0.020 |
Why?
|
| Phenelzine | 1 | 1988 | 1 | 0.020 |
Why?
|
| Imipramine | 1 | 1988 | 4 | 0.020 |
Why?
|
| Epilepsy | 1 | 1989 | 68 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1990 | 163 | 0.020 |
Why?
|
| Dangerous Behavior | 1 | 1988 | 21 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2011 | 228 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2012 | 351 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Public Policy | 1 | 1988 | 33 | 0.020 |
Why?
|
| Educational Status | 1 | 1988 | 257 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1990 | 267 | 0.020 |
Why?
|
| Sample Size | 1 | 2007 | 53 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 1987 | 42 | 0.020 |
Why?
|
| Patient Care | 1 | 1988 | 71 | 0.020 |
Why?
|
| Dothiepin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Dibenzothiepins | 1 | 1986 | 2 | 0.020 |
Why?
|
| Succinates | 1 | 1986 | 3 | 0.020 |
Why?
|
| Codeine | 1 | 1986 | 7 | 0.020 |
Why?
|
| Public Health | 1 | 1988 | 147 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 780 | 0.020 |
Why?
|
| Migraine Disorders | 1 | 1986 | 39 | 0.020 |
Why?
|
| Acetaminophen | 1 | 1986 | 49 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2012 | 543 | 0.020 |
Why?
|
| Sensation | 1 | 1985 | 16 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1988 | 790 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 197 | 0.020 |
Why?
|
| Movement | 2 | 1983 | 132 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1985 | 80 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 1984 | 32 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 1984 | 72 | 0.020 |
Why?
|
| Propiophenones | 1 | 1983 | 1 | 0.020 |
Why?
|
| Panic | 1 | 1983 | 2 | 0.020 |
Why?
|
| Schizophrenia, Catatonic | 1 | 1983 | 1 | 0.020 |
Why?
|
| Phobic Disorders | 1 | 1983 | 17 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1983 | 78 | 0.020 |
Why?
|
| Fear | 1 | 1983 | 54 | 0.020 |
Why?
|
| Affective Symptoms | 2 | 1980 | 14 | 0.020 |
Why?
|
| Posture | 1 | 1983 | 118 | 0.020 |
Why?
|
| Precipitating Factors | 1 | 2001 | 3 | 0.020 |
Why?
|
| Nystagmus, Pathologic | 1 | 1981 | 2 | 0.010 |
Why?
|
| Skin Temperature | 2 | 1979 | 15 | 0.010 |
Why?
|
| Methods | 1 | 1981 | 42 | 0.010 |
Why?
|
| Relaxation Therapy | 2 | 1979 | 25 | 0.010 |
Why?
|
| Auditory Perception | 1 | 1981 | 30 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 1980 | 24 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 1979 | 3 | 0.010 |
Why?
|
| Social Change | 1 | 1979 | 17 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 1979 | 36 | 0.010 |
Why?
|
| Probability | 1 | 1979 | 165 | 0.010 |
Why?
|
| Hysteria | 1 | 1978 | 1 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1978 | 14 | 0.010 |
Why?
|
| Syndrome | 1 | 1978 | 141 | 0.010 |
Why?
|
| Life Change Events | 1 | 1978 | 69 | 0.010 |
Why?
|
| Massachusetts | 1 | 1984 | 2038 | 0.010 |
Why?
|
| Social Environment | 1 | 1978 | 99 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1978 | 115 | 0.010 |
Why?
|
| Prognosis | 1 | 1981 | 1259 | 0.010 |
Why?
|
| Kidney | 1 | 1979 | 325 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 98 | 0.010 |
Why?
|
| Curriculum | 1 | 1979 | 466 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 861 | 0.010 |
Why?
|
| Depressive Disorder, Major | 1 | 1978 | 225 | 0.010 |
Why?
|
| Anxiety | 1 | 1978 | 275 | 0.010 |
Why?
|
| Cephalometry | 1 | 1995 | 13 | 0.010 |
Why?
|
| Butyrophenones | 1 | 1974 | 1 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1978 | 382 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 17868 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1978 | 493 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 1337 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 93 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1990 | 112 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 1988 | 13 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1988 | 120 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1988 | 80 | 0.010 |
Why?
|
| Random Allocation | 1 | 1988 | 202 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1990 | 663 | 0.010 |
Why?
|
| HIV | 1 | 1987 | 80 | 0.010 |
Why?
|
| Xerostomia | 1 | 1986 | 7 | 0.010 |
Why?
|
| Constipation | 1 | 1986 | 16 | 0.010 |
Why?
|
| Nausea | 1 | 1986 | 32 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1986 | 120 | 0.000 |
Why?
|
| Anxiety Disorders | 1 | 1986 | 133 | 0.000 |
Why?
|
| Sleep | 1 | 1986 | 180 | 0.000 |
Why?
|
| Bupropion | 1 | 1983 | 9 | 0.000 |
Why?
|
| Saccades | 1 | 1981 | 19 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1988 | 1055 | 0.000 |
Why?
|
| Kidney Concentrating Ability | 1 | 1979 | 3 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1979 | 10 | 0.000 |
Why?
|
| Masseter Muscle | 1 | 1979 | 1 | 0.000 |
Why?
|
| Creatinine | 1 | 1979 | 107 | 0.000 |
Why?
|
| Glomerular Filtration Rate | 1 | 1979 | 73 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1988 | 4230 | 0.000 |
Why?
|